Generic Threat

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-07-01-2001
Volume 0
Issue 0

Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.

Articles in this issue
Amgen's New Dream Team
Pharmacies: OTC Price Wars
One Disease at a Time
Overview of the Industry: A World of Opportunities
The Power Shift
Access: Novartis Gives It Away
A Giant Stumbles
CRO's Cross Over NOW
Overruled: No More Dual Pricing
Submerged
Generic Threat
Bottom Line Booster
Recent Videos
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Most Effective Strategies to Close the Innovation Gap in Women’s Health
Root Causes of Innovation Gap in Women’s Health
Fred Aslan
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Related Content
Stock.adobe.com

Halia Therapeutics Wins Novo Nordisk Golden Ticket

Mike Hollan
March 24th 2025
Article

The biotech won the award for its work in obesity and inflammation treatment.

Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, Founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry, and how digital health platforms could potentially help offset them.

Pharma Pulse 3/24/25: Boosting Patient Empowerment, Email Remains Leading Security Risk in Healthcare & more

Pharma Pulse 3/24/25: Boosting Patient Empowerment, Email Remains Leading Security Risk in Healthcare & more

Miranda Schmalfuhs
March 24th 2025
Article

The latest news for pharma industry insiders.

Jennifer Butler

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
March 11th 2025
Podcast

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

Johnson & Johnson to Invest Over $55 Billion in US Manufacturing Facilities

Johnson & Johnson to Invest Over $55 Billion in US Manufacturing Facilities

Don Tracy, Associate Editor
March 21st 2025
Article

The investment, which is a 25% increase from previous years, will support three new advanced manufacturing facilities, expansions at existing sites, and R&D efforts.

Phase III Trial Shows Novartis’ Gene Therapy Significantly Improves Spinal Muscular Atrophy Outcomes

Phase III Trial Shows Novartis’ Gene Therapy Significantly Improves Spinal Muscular Atrophy Outcomes

Don Tracy, Associate Editor
March 21st 2025
Article

Results from the STEER and STRENGTH studies showed that OAV101 IT led to a 2.39-point improvement in motor function in patients with spinal muscular atrophy.